Josep M. Llibre

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Josep M. Llibre, Chien‐Ching Hung, Cynthia Brinson et al. · The Lancet · 2018 · 347 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 329 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection

Estebán Martínez, Juan A. Arnaiz, Daniel Podzamczer et al. · New England Journal of Medicine · 2003 · 293 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019

Dima Dandachi, Grant Geiger, Mary W. Montgomery et al. · Clinical Infectious Diseases · 2020 · 231 citations · Full text

Health Professions, Internal Medicine, Electronic Health Records +9

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

Estebán Martínez, María Larrousse, Josep M. Llibre et al. · AIDS · 2010 · 192 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17